Fibrosis News and Research

RSS

Fibrosis is the growth of fibrous tissue.

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

New treatment for vaso-occlusive crisis in sickle cell patients

GlycoMimetics, Inc. (GMI), a clinical-stage biotechnology company that is developing a new class of glycobiology-based therapies for a broad range of indications, today announced that a pilot study of the company’s lead candidate, GMI-1070, is underway in sickle cell patients. The first patients in this pilot study were treated at Children’s Hospital & Research Center Oakland in California.

4 Sep 2009

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Masimo (Nasdaq: MASI), the inventor of Pulse CO-Oximetry(TM) and Measure-Through Motion and Low-Perfusion pulse oximetry, announced today that Children's Hospital & Research Center Oakland has completed its system-wide conversions to Masimo Rainbow SET Pulse CO-Oximetry technology.

2 Sep 2009

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Bile acids are known to be key regulators of lipid, glucose and overall energy metabolism. Bile acid activation of the G protein-coupled receptor TGR5 has been shown to induce energy expenditure in muscle and brown fat, thereby conferring resistance to weight gain.

2 Sep 2009

Researchers demystify polar body analysis reproduction technique

Three out of ten women who undergo polar body diagnosis go on to have a child. The extensive technique of polar body analysis (PBA) is described by researchers in reproductive medicine at Lübeck in an article in the current edition of Deutsches Ärtzeblatt International, in which they present three successful cases and one failure.

31 Aug 2009

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

It is still unknown why the natural history of chronic disease caused by hepatitis C virus (HCV), which currently infects 3% of the world's population, varies from mild in some patients to rapidly progressing in others. Age, sex, alcohol consumption and liver sensitivity to gut-derived bacterial endotoxins, were the early factors defined to enhance the risk of fibrosis progression.

27 Aug 2009

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Morria Biopharmaceuticals Plc, a biopharmaceutical company focusing on novel, non-steroidal anti-inflammatory drugs, announced today that it has received written approval to commence its Phase II clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX6.

26 Aug 2009

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Ho Jeong and his colleague from Korea presented a case of duodenal obstruction after successful selective transcatheter arterial embolization (TAE) for a duodenal diverticular hemorrhage. Their study will be published on August 14, 2009 in the World Journal of Gastroenterology.

26 Aug 2009

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Accumulating evidence suggests that connective tissue growth factor (CCN2) plays a central role in fibrotic conditions in many organ systems. Fibrosis is a scarring condition that is characterized by excessive collagen production that impedes normal cell function and can cause organ dysfunction and failure.

25 Aug 2009

Toshiba America Medical Systems installs its 800th Vantage 1.5T MR system

Toshiba America Medical Systems, Inc., an industry leader in magnetic resonance (MR) technology, reached a significant achievement in installing its 800th Vantage 1.5T MR system at Elkview General Hospital in Hobart, Okla. Elkview is using the Vantage system for orthopedic, neuro and abdominal imaging.

25 Aug 2009

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

REGENERX BIOPHARMACEUTICALS, INC. (the “Company” or “RegeneRx”) announced today that it received a “Notice of Allowance” in Europe for its patent application: Inhibition or Reversal of Skin Aging by Actin-Sequestering Peptides.

25 Aug 2009

University of Michigan discovers new gene target for treating idiopathic pulmonary fibrosis

Researchers at the University of Michigan have discovered that targeting of a novel gene utilizing genetic and pharmacologic strategies was successful in treating pulmonary fibrosis in mice and will be developed for future testing in humans.

24 Aug 2009

Research study reveals that mortality remains high in patients with pulmonary arterial hypertension

Mortality remains high among patients with pulmonary arterial hypertension awaiting lung transplant, despite changes to the allocation system that were designed to reduce mortality and increase the equitable distribution of donor organs, according to new research out of University of California San Francisco.

24 Aug 2009

Scientists to discuss effective treatments for serious diseases at Functional Genomics/Chemical Biology conference

A cure for cystic fibrosis, HIV-fighting 'Trojan horses', new pharmaceuticals from the ocean. Chemical biologists use new and innovative approaches to discover medications of the future. On 24 August, some of the field's most prominent researchers will attend an international conference in Gothenburg, Sweden.

24 Aug 2009

Innovotech reports year-on-year revenue increase for second-quarter 2009

Innovotech Inc. (TSX VENTURE:IOT) today announced its unaudited financial and operational results for the three and six month periods ended June 30, 2009.

21 Aug 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Roche (SIX: ROG.VX; RO.S, OTCQX: RHHBY) and InterMune, Inc. (Nasdaq: ITMN) today announced that the first patient has been dosed in a Phase 2b study evaluating the hepatitis C virus (HCV) protease inhibitor, RG7227/ ITMN-191, in combination with PEGASYS(R) (pegylated interferon alfa-2a) and COPEGUS(R) (ribavirin). The study, to be conducted at 45 sites globally, will further define the safety and efficacy profile of RG7227/ ITMN-191, for a treatment duration of up to 24 weeks. Approximately 300 treatment-naive patients chronically infected with HCV genotype 1 - the most difficult to treat form of the virus - will participate.

20 Aug 2009

Novel genome-analysis strategy to speed search for gene-disease links

University of Washington (UW) researchers have successfully developed a novel genome-analysis strategy for more rapid, lower cost discovery of possible gene-disease links. By saving time and lowering expenses, the approach makes it feasible for scientists to search for disease-causing genes in people with the same inherited disorder but without any family ties to each other.

18 Aug 2009

Secretary Sebelius announces Senate confirmation of Dr. Francis Collins as Director of NIH

HHS Secretary Kathleen Sebelius announced today that the United States Senate unanimously confirmed Dr. Francis Collins as the next Director of the National Institutes of Health.

10 Aug 2009

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

At least 50 research projects so far, supported by more than $10 million in stimulus grants from the National Institutes of Health, are expected to lead to new discoveries at Emory University that will improve medical treatment, create new jobs, and provide additional educational opportunities for students. Emory has received half of all the NIH ARRA grants awarded to Georgia academic institutions thus far.

9 Aug 2009

Scientists discover link between mutations in INPP5E gene and ciliopathies

An international team of scientists, led by researchers at the University of California, San Diego School of Medicine, have discovered a connection between mutations in the INPP5E gene and ciliopathies. Their findings, which may lead to new therapies for these diseases, will appear in the online edition of Nature Genetics on August 9.

9 Aug 2009

Fibrosis News and Research

Further Reading

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

New treatment for vaso-occlusive crisis in sickle cell patients

Children's Hospital Oakland converts to Masimo Rainbow SET Pulse CO-Oximetry technology

Paper discussing the mechanism of the selective TGR5 agonist INT-777 published in Cell Metabolism

Researchers demystify polar body analysis reproduction technique

Relationship between the CD14 variation and the formation of portal lymphoid aggregates discovered

Morria Biopharmaceuticals receives approval to commence its Phase II clinical trial on MRX6

Duodenal obstruction observed after selective transcatheter arterial embolization for a duodenal diverticular hemorrhage

Study suggests that connective tissue growth factor plays a vital role in liver fibrosis progression

Toshiba America Medical Systems installs its 800th Vantage 1.5T MR system

RegeneRx announces the receipt of a Notice of Allowance in Europe for its patent application

University of Michigan discovers new gene target for treating idiopathic pulmonary fibrosis

Research study reveals that mortality remains high in patients with pulmonary arterial hypertension

Scientists to discuss effective treatments for serious diseases at Functional Genomics/Chemical Biology conference

Innovotech reports year-on-year revenue increase for second-quarter 2009

InterMune receives $20 million event payment from Roche for initiating the Phase 2b trial of RG7227/ ITMN-191

Novel genome-analysis strategy to speed search for gene-disease links

Secretary Sebelius announces Senate confirmation of Dr. Francis Collins as Director of NIH

NIH stimulus funding supports Emory - grants to advance research, create jobs, support students

Scientists discover link between mutations in INPP5E gene and ciliopathies

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News